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The mechanisms regulating tumor-associated inflammation are incompletely understood. In this issue of
Cancer Cell, Rutkowski and colleagues indicate that TLR5 signaling deficiency, which occurs in 10% of
the population, changes interactions with commensal microbiota and deregulates a cascade of inflammatory
events that can suppress or accelerate extraintestinal cancers.Cancer and inflammation were first linked
more than 150 years ago by Robert
Virchow, who observed that leukocytes
frequently infiltrate tumors. Yet, the role
of the immune system in malignancy has
only recently come under more extensive
study. At present, we understand that
distinct immune components, which
define a so-called immune contexture
(Fridman et al., 2012), can either repress
or promote cancer. Recent evidence
also indicates that intestinal commensal
bacteria profoundly influence immune
cell activity in health and disease (Hooper
et al., 2012) and modulate disease-asso-
ciated immune responses to therapy
even at extraintestinal sites (Iida et al.,
2013; Viaud et al., 2013). Therefore,
uncovering which microbiota-host inter-
actions cause or prevent disease should
increase our understanding of cancer
and possibly offer new vantage points
for therapy.
In this issue of Cancer Cell, Rutkowski
et al. (2015) report that Toll-like receptor
5 (TLR5), a pattern recognition receptor
that recognizes bacteria-derived prod-
ucts, can greatly affect extraintestinal
tumor progression through differential
modulation of systemic inflammation
and tumor-associated immunity. The find-
ings presented in this study might have
broad consequences, because TLR5
loss-of-function mutations are frequent
in humans (Casanova et al., 2011).
Using a conditional genetic mouse
model of sarcoma driven by Kras and
Trp53 alterations, Rutkowski et al. (2015)
initially found that TLR5 deficiency
decreased systemic interleukin 6 (IL-6)
serum levels and delayed tumor progres-
sion. In this model IL-6 also controlled
myeloid cell mobilization, which is associ-
ated with accelerated tumor progression,according to previous studies (Gabrilo-
vich et al., 2012). Interestingly, depleting
commensal microbiota by orally adminis-
tering antibiotics to TLR5-responsive
mice was sufficient to control IL-6 levels,
myeloid cell mobilization, and sarcoma
outgrowth. Bacterial depletion also pre-
vented accumulation of tumor-infiltrating
gd T cells, which can mediate immu-
nosuppressive functions and promote
cancer progression (Peng et al., 2007).
Separate experiments involving anti-
body-mediated depletion or adoptive
transfer of gd T cells further indicated
that the presence of this T cell subset ac-
celerates malignant progression in TLR5-
responsive hosts. These data show
that TLR5-mediated host recognition of
commensal bacteria can regulate tumor
progression by affecting the tumor’s
immune contexture.
Rutkowski and colleagues further
report that, in the presence of commensal
bacteria, gd T cells produce the immuno-
suppressive molecule galectin-1 (Rubin-
stein et al., 2004), thereby suggesting
that microbiota also affect the functions
of tumor-associated immune cells. Mech-
anistic studies indicate that myeloid
cells can produce adenosine, which helps
upregulate galectin-1 expression in gd
T cells. Also, by generating chimeras
with gd- and galectin-1-deficient bone
marrow, the authors found that galectin-
1 secreted by gd T cells is sufficient
to accelerate Kras/p53-driven sarcoma
growth in mice.
Rutkowski et al. (2015) went on to
assess consequences of TLR5 loss-of-
function in mouse models of other extra-
intestinal cancers and found that TLR5
deficiency does not always suppress
tumor growth. In fact, they determined
that the A7C11 breast carcinoma cellCancer Cellline grows even faster in TLR5-deficient
hosts than in their wild-type counterparts.
The precise mechanisms that dictate
whether TLR5 signaling will promote or
suppress cancer require further study,
yet initial findings indicate that cytokines
can play a role. In TLR5-sufficient mice,
several tumors (e.g., the MPKAS cell line
derived from axillary tumors of the genetic
Kras/Trp53 mouse model and orthotopic
ovarian cancers) increased systemic IL-
6 serum levels and likely depended on
IL-6 to grow, whereas A7C11 breast tu-
mors did not. Instead, A7C11-bearing
mice showed increased IL-17 serum
levels in TLR5-deficient mice. Adminis-
tering IL-17 blocking antibodies
controlled A7C11 tumor progression.
Also, commensal bacteria depletion in
these mice reduced IL-17 levels and
controlled tumor growth. Administering
IL-17 blocking antibodies also controlled
MPKAS tumor growth, but only when IL-
6 was also blocked.
Taken together, the murine data sug-
gest that IL-6 and IL-17 differ in their
ability to influence tumor-promoting
inflammation; IL-6 may be induced pre-
ferentially in TLR5-competent hosts by
the TLR itself and then drive malignant
progression, whereas IL-17 may increase
malignant progression only in the
absence of both IL-6 and functional
TLR5 signaling. Yet, both IL-6 and IL-17
are affected by commensal microbiota
and eventually drive systemic changes
that impact the immune contexture and
foster tumor progression.
That microbiota-TLR5 interactions in
mice control systemic inflammation
and cancer might also be relevant for
breast and ovarian cancer patients
(Figure 1). Tumors from breast cancer
patients with TLR5R392x have higher27, January 12, 2015 ª2015 Elsevier Inc. 1
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Variable impact of TLR5 signaling deficiency:
Figure 1. Host-Microbiota Interactions Impact Tumor Immune Contexture
Tumor growth is sensitive to the inflammatory milieu. Sensing of commensal bacteria residing in the
intestines elicits systemic cytokine responses that can be altered by mutation of TLR5 or through oral
antibiotics. Changes in systemic cytokine levels can either promote or impair tumor growth depending
upon the type of cancer involved.
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zygous for the wild-type TLR5 allele.
Retrospective analysis revealed that
TLR5R392x breast cancer patients may
have poorer overall survival compared
to patients with wild-type TLR5 alleles.
In contrast, retrospective analysis indi-
cated that TLR5R392X ovarian cancer pa-
tients may have improved survival. This
is consistent with mouse model data
indicating that TLR5 signaling can accel-
erate ovarian cancer progression. As in
the murine studies, TLR5-responsive
ovarian cancer patients showed higher
systemic IL-6 levels, whereas TLR5-un-
responsive patients showed decreased
numbers of gd T cells and myeloid cells
in the tumor stroma. All in all, ovarian
cancer seems more IL-6 dependent in2 Cancer Cell 27, January 12, 2015 ª2015 Elthe presence of functional TLR5
signaling, whereas breast cancer may
be preferentially driven by IL-17 in the
absence of functional TLR5 (Figure 1).
However, the relevance of, and depen-
dence on, systemic IL-6 and IL-17 cyto-
kines during tumor progression will
require follow-up studies.
Interestingly, intestinal bacterial popu-
lations can regulate host immunity not
only locally, but also systemically (Hoop-
er et al., 2012; Ichinohe et al., 2011),
but we do not yet know whether, or
to what extent, certain intestinal micro-
bial species define the immune contex-
ture of, e.g., extraintestinal tumors.
The present study indicates that the
microbiome from Tlr5–/– mice cannot
be transferred to co-housed wild-typesevier Inc.mice, thereby suggesting that wild-type
mice exhibit colonization resistance to
the transferred bacteria. Instead, trans-
planting microbiota from Tlr5–/– mice
to germ-free recipients may overcome
colonization resistance barriers and
facilitate mechanistic studies of specific
microbes and their association with im-
mune contexture and cancer develop-
ment. Specific associations between
microbiota and tumor immune contex-
ture could provide a proxy for assaying
the human tumor microenvironment
by characterizing microbial species in
the human intestines. The human tumor
microenvironment is very difficult to
characterize in vivo, so sequencing
human microbiomes would be a conve-
nient means to provide critical patient
information.
Whether TLR5 loss-of-function can
affect responses to anticancer therapy
also remains unknown. Because the
intestinal commensal microbiota can
impact chemotherapy and immuno-
therapy (Viaud et al., 2013; Iida et al.,
2013) and TLR5-deficiency perturbs the
microbiota, the altered microbiota in a
TLR5-deficient setting could also affect
responses to treatment. Follow-up work
examining how TLR5 signaling deficiency
alters drug-induced immune responses
and effective cancer control could prove
valuable in personalizing cancer treat-
ments. Because TLR5 is one of many
innate immune regulators, evaluating
common deficiencies or polymorphisms
in other innate immune pathways could
also provide insight into the mechanisms
regulating systemic inflammation and
influencing tumor growth and response
to therapy.REFERENCES
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Oncogene-induced senescence (OIS) is thought to be a barrier to malignant transformation resulting from
the strong activation of oncogenes. In this issue of Cancer Cell, Damsky and colleagues suggest activation
of mTORC1 and mTORC2 is required for OIS evasion in human melanomas harboring oncogenic BRAF
mutations.Cellular senescence was described more
than five decades ago as an in vitro
permanent growth arrest in primary fibro-
blasts after long-term culture. Subse-
quent work has shown that senescence
can be induced by a wide variety of
extra- and intracellular stresses. The
molecular effectors of senescence have
been well characterized, involving the
activation of canonical tumor suppres-
sors like p53, p16Ink4a, and RB (Kuilman
et al., 2010). Perhaps one of the most
surprising findings regarding senescence
has been the discovery that the strong
activation of certain oncogenes, the
very agents of cancer, will potently
induce senescence in cells with intact
p53 and p16Ink4a-RB signaling (Serrano
et al., 1997). The discovery of this ‘‘onco-
gene-induced senescence’’ (OIS) has
troubled many cancer researchers. How
could any normal cell ever give rise to a
cancer if oncogene activation provokes
a permanent growth arrest? A variety of
explanations have been advanced in an
attempt to resolve this seeming paradox.
A few of the more popular notions have
been that OIS (or even senescence in
general) is merely an in vitro artifact,that p53 or p16Ink4a loss actually pre-
cedes strong oncogene activation in can-
cers, or that cellular senescence is in
some cases not permanent as previously
conceived.
Support for the occurrence of OIS
in vivo is probably stronger for melanoma,
a common and lethal human skin cancer,
than for any other form of human cancer.
The overexpression of common onco-
genic drivers of melanoma, e.g., mutant
Nras or Braf, potently inducesmelanocyte
OIS in vitro in a p16Ink4a- and p53-depen-
dent manner. The expression of markers
of senescence such as p16Ink4a can be
demonstrated in precursor lesions of mel-
anoma (nevi) harboring BRAF mutations,
most commonly V600E. These observa-
tions have suggested that many nevi are
would-be cancers but are successfully in-
terdicted by the senescence machinery.
The fact that the vast majority of nevi
never progress to melanoma speaks to
the robustness of OIS as a defense mech-
anism against cancer. It appears clearly
true, however, that cells in a very small
fraction of nevi evade OIS to cause the
roughly 70,000 melanoma cases per
year in the US alone.Against this background, Damsky et al.
(2015; in this issue of Cancer Cell) have
tackled theOIS problem, focusing onmel-
anoma. To do this, the authors use an
array of state-of-the-art conditional mu-
rine models to comprehensively analyze
the transitions from prearrested, to post-
arrested, to transformed melanocytes.
In accord with prior work (Dhomen et al.,
2009; Michaloglou et al., 2005), the au-
thors demonstrate that disruption of the
Cdkn2a (Ink4a/Arf) locus alone is not
sufficient to permit BrafV600E-inducedme-
lanoma, suggesting that activated Raf
signaling engages an antiproliferative res-
ponse independent of Cdkn2a signaling
(Figure 1). This observation is in accord
with prior work suggesting that activated
Ras-Raf signaling induces a compensa-
tory repression of PI3K-Akt and Raf-Mek
signaling (Courtois-Cox et al., 2006). In
the present study, however, the combi-
nation of Braf activation and Cdkn2a
loss was sufficient to prime progression
of nevi to melanoma, presumably in the
setting of additional stochastic events.
By including a GFP expressed specifically
in melanocytes in their murinemodels, the
authors were able to purify uncultured27, January 12, 2015 ª2015 Elsevier Inc. 3
